Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer

Journal of Urology

Volumn 161, Issue 5, 1999, Pages 1525-1529

  Ramos, Christian G ^a   Carvalhal, Gustavo F ^a   Smith, Deborah S ^a   Mager, Douglas E ^a   Catalona, William J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Urologic Surgery   (United States)

Author keywords

Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SURVIVAL RATE;

EID: 0032824355     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68944-6     Document Type: Article

References (19)

1. Jacobsen, S. J., Katusic, S. K., Bergstralh, E. J., Oesterling, J. E., Ohrt, D., Klee, G. G., Chute, C. G. and Lieber, M. M.: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J.A.M.A., 274: 1445, 1995.
2. Blute, M. L., Zincke, H. and Farrow, G. M.: Long-term followup of young patients with stage A adenocarcinoma of the prostate. J. Urol., 136: 840, 1986.
3. Epstein, J. I., Paull, G., Eggleston, J. C. and Walsh, P. C.: Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J. Urol., 136: 837, 1986.
4. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
5. Smith, D. S., Humphrey, P. A. and Catalona, W. J.: The early detection of prostate carcinoma with prostate specific antigen. The Washington University experience. Cancer, 80: 1852, 1997.
6. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
7. Chodak, G. W.: Questioning the value of screening for prostate cancer in asymptomatic men (Editorial). Urology, 42: 116, 1993.
8. Belville, W. D.: Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Sem. Urol. Oncol., 13: 181, 1995.
9. Catalona, W. J. and Smith, D. S.: Cancer recurrence and survival rates after anatomical radical retropubic prostatectomy for prostate cancer: intermediate-term results. J. Urol., part 2, 160: 2428, 1998
10. Abbas, F., Kattan, M. V., Wheeler, T. M., Adler, H. L. and Scardino, P. T.: Survival and cancer control for patients with cT1-T2 prostate cancer with intent to treat by radical prostatectomy. J. Urol., part 2, 159: 252, abstract 964,1998.
11. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
12. Carter, H. B., Sauvageot, J., Walsh, P. C. and Epstein, J. I.: Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J. Urol., 157: 2206, 1997.
13. Humphrey, P. A., Keetch, D. E., Smith, D. S., Shepherd, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
14. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., part 2, 152: 1732, 1994.
15. Stormont, T. J., Farrow, G. M., Myers, R. P., Blute, M. L., Zincke, H., Wilson, T. M. and Oesterling, J. E.: Clinical stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology, 41: 3, 1993.
16. Walsh, P. C., Lepor, H. and Eggleston, J. C.: Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate, 4: 473, 1993.
17. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. W.: Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. J.A.M.A., 270: 948, 1993.
18. Stamey, T. A., Sözen, T. S., Yemoto, CH. M. and McNeal, J. E.: Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J. Urol., 159: 2009, 1998.
19. Littrup, P. J.: Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society. Cancer, 80: 1864, 1997.